Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q1- Text added to 2020 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
add, ASUNo, begun, buildingand, byReference, cardiac, carryforward, cease, Certification, chronic, compensatory, compromised, contractility, Description, Director, duly, ejection, Exhibit, FiledHerewith, formatted, Formor, fraction, grantedduring, hereinfrom, Hineline, Impression, infrastructureand, Inline, Inodilatorsin, Interactive, inthe, Language, Lawrence, lumateperoneapproved, lumateperonefor, lumateperonemay, mortality, NasdaqBiotechnology, nonclinical, ofCAPLYTA, ofJune, onDecember, onForm, ourselling, output, Page, resistance, scale, Schedule, secondary, Sharon, situation, studyby, symptomatic, thereunto, thethree, thetime, thisForm, tosatisfy, undersigned, unvestedMilestone, unvestedtime, vascular, vi, whichresulted, XBRL
Valuein 2020 Q1 filing- Value in 2020 Q2 filing
Original filings
Filing view